BACKGROUND AND OBJECTIVES: The objective of this study was to assess the reporting of randomized clinical trials investigating procedural treatments (eg, nerve blocks, targeted drug delivery) for cancer pain, with a focus on aspects that are particularly challenging in these trials. METHODS: This article presents results from a systematic review of reporting of randomized clinical trials of procedural interventions for cancer pain. Articles were identified by searching PubMed from 1966 to June 2014. Data related to quality of reporting are presented for early (1985-2004) and late periods (2005-2014). RESULTS: A total of 35 published trials were included. Approximately two-thirds of the articles clearly indicated the level of blinding. Only 26% reported a primary outcome measure. Less than half explicitly reported the number of patients who completed the trial, and only 1 reported a method that was used to accommodate missing data. Almost one-third of articles included a responder analysis, all of which specified the definition of a responder. CONCLUSIONS: The goal of highlighting these deficiencies in reporting is to promote transparent reporting of details affecting the completion and interpretation of procedural cancer pain trials so that their quality can be more easily evaluated.
BACKGROUND AND OBJECTIVES: The objective of this study was to assess the reporting of randomized clinical trials investigating procedural treatments (eg, nerve blocks, targeted drug delivery) for cancer pain, with a focus on aspects that are particularly challenging in these trials. METHODS: This article presents results from a systematic review of reporting of randomized clinical trials of procedural interventions for cancer pain. Articles were identified by searching PubMed from 1966 to June 2014. Data related to quality of reporting are presented for early (1985-2004) and late periods (2005-2014). RESULTS: A total of 35 published trials were included. Approximately two-thirds of the articles clearly indicated the level of blinding. Only 26% reported a primary outcome measure. Less than half explicitly reported the number of patients who completed the trial, and only 1 reported a method that was used to accommodate missing data. Almost one-third of articles included a responder analysis, all of which specified the definition of a responder. CONCLUSIONS: The goal of highlighting these deficiencies in reporting is to promote transparent reporting of details affecting the completion and interpretation of procedural cancer pain trials so that their quality can be more easily evaluated.
Authors: John P A Ioannidis; Stephen J W Evans; Peter C Gøtzsche; Robert T O'Neill; Douglas G Altman; Kenneth Schulz; David Moher Journal: Ann Intern Med Date: 2004-11-16 Impact factor: 25.391
Authors: Robert H Dworkin; Dennis C Turk; Sarah Peirce-Sandner; Laurie B Burke; John T Farrar; Ian Gilron; Mark P Jensen; Nathaniel P Katz; Srinivasa N Raja; Bob A Rappaport; Michael C Rowbotham; Misha-Miroslav Backonja; Ralf Baron; Nicholas Bellamy; Zubin Bhagwagar; Ann Costello; Penney Cowan; Weikai Christopher Fang; Sharon Hertz; Gary W Jay; Roderick Junor; Robert D Kerns; Rosemary Kerwin; Ernest A Kopecky; Dmitri Lissin; Richard Malamut; John D Markman; Michael P McDermott; Catherine Munera; Linda Porter; Christine Rauschkolb; Andrew S C Rice; Cristina Sampaio; Vladimir Skljarevski; Kenneth Sommerville; Brett R Stacey; Ilona Steigerwald; Jeffrey Tobias; Ann Marie Trentacosti; Ajay D Wasan; George A Wells; Jim Williams; James Witter; Dan Ziegler Journal: Pain Date: 2012-04-09 Impact factor: 6.961
Authors: Shannon M Smith; Daniel R Chang; Anthony Pereira; Nirupa Shah; Ian Gilron; Nathaniel P Katz; Allison H Lin; Michael P McDermott; Bob A Rappaport; Michael C Rowbotham; Cristina Sampaio; Dennis C Turk; Robert H Dworkin Journal: Pain Date: 2012-09-15 Impact factor: 6.961
Authors: Jennifer S Gewandter; Shannon M Smith; Andrew McKeown; Laurie B Burke; Sharon H Hertz; Matthew Hunsinger; Nathaniel P Katz; Allison H Lin; Michael P McDermott; Bob A Rappaport; Mark R Williams; Dennis C Turk; Robert H Dworkin Journal: Pain Date: 2013-11-23 Impact factor: 6.961